Transgene Biotek Limited

TRABI6

INE773D01018

Biotechnology & Medical Research

Market Closed - Bombay S.E. Other stock markets 06:00:56 2024-06-26 am EDT			5-day change	1st Jan Change
8.8 ^INR	0.00%		-1.23%	-10.84%

May. 30	Transgene Biotek Limited Reports Earnings Results for the Fourth Quarter and Full Year Ended March 31, 2024	CI
Feb. 14	Transgene Biotek Limited Reports Earnings Results for the Third Quarter and Nine Months Ended December 31, 2023	CI

Transgene Biotek Limited Approves Licensing Agreement of TrabiORAL Technology with GVK Bio

May 28, 2020 at 02:02 am EDT

Transgene Biotek Limited announced that in its board meeting, the company has discuss and approve Licensing Agreement of TrabiORAL technology with GVK Bio.

Latest news about Transgene Biotek Limited

Transgene Biotek Limited Reports Earnings Results for the Fourth Quarter and Full Year Ended March 31, 2024	May. 30	CI
Transgene Biotek Limited Reports Earnings Results for the Third Quarter and Nine Months Ended December 31, 2023	Feb. 14	CI
Transgene Biotek Limited Reports Earnings Results for the Second Quarter Ended September 30, 2023	Nov. 14	CI
Transgene Biotek Limited Approves Closure of Subsidiary Company Peroral Bio Private Limited	23-08-05	CI
Transgene Biotek Limited Reports Earnings Results for the First Quarter Ended June 30, 2023	23-08-05	CI
Transgene Biotek Limited Reports Earnings Results for the Fourth Quarter Ended March 31, 2023	23-05-30	CI
Transgene Biotek Limited Reports Earnings Results for the Fourth Quarter and Full Year Ended March 31, 2023	23-05-30	CI
Transgene Biotek Limited Reports Earnings Results for the Third Quarter Ended December 31, 2022	23-02-14	CI
Transgene Biotek Limited Reports Earnings Results for the Second Quarter and Six Months Ended September 30, 2022	22-11-12	CI
Transgene Biotek Limited Reports Earnings Results for the First Quarter Ended June 30, 2022	22-08-13	CI
Transgene Biotek Limited Reports Earnings Results for the Fourth Quarter Ended March 31, 2022	22-05-30	CI
Transgene Biotek Limited Reports Earnings Results for the Full Year Ended March 31, 2022	22-05-30	CI
Transgene Biotek Limited Reports Earnings Results for the Third Quarter Ended December 31, 2021	22-02-14	CI
Transgene Biotek Limited Reports Earnings Results for the Second Quarter and Six Months Ended September 30, 2021	21-11-12	CI
Transgene Biotek Limited Reports Earnings Results for the First Quarter Ended June 30, 2021	21-08-14	CI
Transgene Biotek Limited Reports Earnings Results for the Fourth Quarter Ended March 31, 2021	21-06-29	CI
Transgene Biotek : in Pact to Provide Oral, Nasal Formulations for COVID-19 Vaccine	21-03-17	MT
Transgene Biotek Limited Reports Unaudited Standalone Earnings Results for the Third Quarter Ended December 31, 2020	21-01-23	CI
Transgene Biotek : Incorporates New Subsidiary	20-12-27	MT
Transgene Biotek Limited Announces Address Changes	20-11-10	CI
Transgene Biotek Limited Reports Unaudited Standalone and Consolidated Earnings Results for the Second Quarter and Six Months Ended September 30, 2020	20-11-10	CI
Transgene Biotek Limited Reports Earnings Results for the First Quarter Ended June 30, 2020	20-08-24	CI
Transgene Biotek Limited Announces Audited Standalone and Consolidated Earnings Results for the Fourth Quarter and Full Year Ended March 31, 2020	20-06-03	CI
Transgene Biotek Limited Approves Licensing Agreement of TrabiORAL Technology with GVK Bio	20-05-28	CI
Transgene Biotek Limited Announces Unaudited Standalone Earnings Results for the Third Quarter Ended December 31, 2019	20-02-04	CI

Chart Transgene Biotek Limited

Duration

Period

More charts

Transgene Biotek Limited is an India-based biotechnology company. The Company is engaged in the research and development of vaccines, oncology and new drug delivery technologies. Its portfolio of products includes oncology, auto-immunity, drug delivery and biogenerics. The Company offers TrabiAAV, which is a platform for the delivery of micro ribonucleic acids (miRNAs), short hairpin RNA (ShRNAs), immunogens developing clinical significance in gene therapy and CRISPR/cas 9 technologies. Its monoclonal antibody therapy is the use of monoclonal antibodies to specifically bind to target cells. Its TrabiORAL is focused on delivering proteins and peptides orally for a variety of human diseases. Its TBL-1203, is used to strengthen cell-mediated immunity and complete elimination of the human immunodeficiency virus (HIV), without any need for retroviral drug therapy. Its Tacrolimus is a drug that suppresses the immune system and is mainly used to prevent rejection of transplanted organs.

Sector

Biotechnology & Medical Research

Calendar

2024-08-11 - Q1 2025 Earnings Release (Projected)

More about the company

Income Statement Evolution

More financial data

Sector Other Biotechnology & Medical Research

	1st Jan change	Capi.
TRANSGENE BIOTEK LIMITED	-10.84%	7.99M
MODERNA, INC.	+23.13%	52.73B
LONZA GROUP AG	+37.49%	39B
IQVIA HOLDINGS INC.	-8.73%	38.52B
ALNYLAM PHARMACEUTICALS, INC.	+28.09%	30.38B
CELLTRION, INC.	-12.26%	26.39B
ICON PUBLIC LIMITED COMPANY	+10.57%	26.08B
UNITED THERAPEUTICS CORPORATION	+45.05%	14.15B
MEDPACE HOLDINGS, INC.	+32.23%	12.6B
BIO-TECHNE CORPORATION	-6.56%	11.51B